Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Sensei Biotherapeutics Inc
SNSE | US
0.78
USD0.37
88.82%
SNSE | US
About Sensei Biotherapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.78
Open
0.42
High
0.87
Low
0.42
Sensei Biotherapeutics Inc. an immuno-oncology company engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101 SNS-103 and SNS-102 monoclonal antibodies which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals Inc. Sensei Biotherapeutics Inc. was incorporated in 1999 and is headquartered in Rockville Maryland.
View LessSNSE | US
Risk
334.7
Sharpe
0.05
Luna's Score
57/100
Recommendation
Hold
Luna says (SNSE | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
438.6%1 month
334.7%3 months
195.5%6 months
172.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.20
Debt to equity
0.10
Debt to assets
0.08
Ent. to EBITDA
1.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-30.98M
MarketCap
19.62M
MarketCap(USD)
19.62M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-45.17
Short ratio
2.70
Short perc.
1.51
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.46
Range1M
0.46
Range3M
0.49
Volumes: Market Activity
Rel. volume
17.60
Price X volume
7.56M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.36 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.20 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 195.52 | - | Riskier |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 19.62M | - | Emerging |
